Saturday 17 October 2026
Export ABSI’s income statement to Excel — free account
Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.25
0.63
−7.09%
Follow ABSI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 7.60 | 1.94 | 1.11 | 2.45 | 2.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 31.53 | 9.68 | 5.47 | 6.72 | 6.33 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 169 | 212 | 193 | 156 | 157 | 140 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.03 | 0.02 | 0.03 | 0.04 | 0.03 | 0.02 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 5 | 5 | 6 | 6 | 5 | 3 | ||||
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | (7) | (14) | (110) | (105) | (110) | (103) | (115) | |||||
| EBT margin, % | — | — | — | (319.61) | (300.27) | (2,297.34) | (1,833.39) | (1,931.90) | (2,272.52) | (4,111.21) | |||||
| Net income | — | 0 | — | (7) | (14) | (101) | (105) | (111) | (103) | (115) | |||||
| Depreciation | — | — | — | 0 | 1 | 7 | 13 | 35 | 13 | 12 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.14 | 0.31 | 0.10 | 0.06 | 0.06 | 0.04 | 0.02 | ||||
| Earnings | — | — | — | (0.43) | (0.93) | (2.08) | (1.15) | (1.20) | (0.94) | (0.84) | |||||
| Cash flow | — | — | — | (0.40) | (0.71) | (1.22) | (0.90) | (0.70) | (0.66) | (0.68) | |||||
| Capex | — | — | — | (0.07) | (0.14) | (0.77) | (0.18) | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.47) | (0.85) | (1.99) | (1.07) | (0.71) | (0.65) | (0.68) | |||||
| Book value | — | — | — | 0.76 | 4.32 | 7.37 | 3.02 | 1.91 | 1.62 | 1.39 | |||||
| Shares, m | — | — | — | 15 | 15 | 50 | 91 | 92 | 110 | 137 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | 70.08 | 70.08 | 85.20 | 35.72 | 59.39 | 63.70 | 170.48 | |||||
| P/B | — | — | — | 0.00 | 0.00 | 1.11 | 0.75 | 1.93 | 1.61 | 2.52 | |||||
| EV/Sales | — | — | — | 78.96 | 78.96 | 31.60 | 6.53 | 40.86 | 36.27 | 119.28 | |||||
| EV/FCF | — | — | — | (8.13) | (8.13) | (1.53) | (0.39) | (3.58) | (2.29) | (3.60) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (6) | (11) | (61) | (81) | (65) | (72) | (93) | ||||
| Capex | — | — | — | (1) | (2) | (38) | (16) | (1) | 1 | 0 | |||||
| Free cash flow | — | — | — | (7) | (13) | (99) | (97) | (65) | (72) | (93) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 10 | 63 | 239 | 157 | 91 | 105 | 127 | ||||
| Total debt | — | — | — | 4 | 8 | 7 | 12 | 8 | 4 | 1 | |||||
| Net debt | — | — | — | (9) | (62) | (256) | (168) | (106) | (124) | (143) | |||||
| Shareholders’ equity | — | — | — | 12 | 67 | 366 | 274 | 176 | 179 | 189 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (245.19) | (91.58) | (40.11) | (28.08) | (41.08) | (47.86) | (53.59) | ||||
| ROIC | — | — | — | (162.00) | (168.01) | (42.83) | (62.56) | (102.78) | (124.30) | (163.37) | |||||
| ROE | — | — | — | 36.56 | 75.76 | (74.63) | (32.76) | (49.08) | (58.04) | (62.50) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Absci Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −46.23% (below 0%: shrinking) | n/m | +15.05% (above 0%: growing) | 100.00% | (1,472.25%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.6B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QURE uniQure N.V. | $1.6B | — (loss-making) | — (loss-making) | +11.00% (above 0%: growing) | n/m | +27.66% (above 0%: growing) | 94.01% | (893.73%) | Compare |
| KRSA Korsana Biosciences, Inc. | $1.5B | — (loss-making) | — (loss-making) | −43.24% (below 0%: shrinking) | n/m | −184.69% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MAZE Maze Therapeutics, Inc. | $1.5B | — (loss-making) | — | — | n/m | +50.21% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABSI Absci Corporation | $1.5B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | |
| IMCR Immunocore Holdings PLC Sponsored ADR | $1.5B | — (loss-making) | 208× | +18.34% (above 0%: growing) | n/m | −40.74% (below 0%: shrinking) | 99.06% | (2.58%) | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +28.14% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 84.11% | (35.05%) | Compare |
| ANAB AnaptysBio, Inc. | $1.5B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| Median of peers | $1.5B | — | — | +1.51% | — | −14.12% | 99.53% | (18.81%) |
Absci Corporation (ABSI) key facts
- Concern: Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024.
- Absci Corporation (ABSI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ABSI traded at $8.25, a market capitalization of $1.5 billion.
- Return on equity was −62.5% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 5.50 (safe zone) for fiscal 2025.